Business & regional news

Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population¹

Company honored for creating the world's first Adaptive deep brain stimulation (aDBS) system for people with Parkinson's

Multicenter ALERT Trial demonstrates potential to advance treatment pathway to minimally invasive heart valve therapies for underserved patient populations

EMBRACE trial to study renal denervation with the Symplicity Spyral™ system and percutaneous coronary intervention (PCI) in the same procedure In SPYRAL HTN ON and OFF MED trials, patients...

Annual recognition honors organizations committed to business integrity through robust ethics, compliance, and governance programs

Empowering endoscopists with meaningful insights

Milestone expands patient access to the first and most studied renal denervation therapy for hypertension.

Infuse™ is the only PMA-approved growth factor bone graft indicated for ALIF, OLIF, and TLIF

Medtronic in India drives awareness on Bradycardia with #DecodeYourRhythm Campaign.

University of Colorado selected as a strategic academic partner given the strength of the capabilities to advance disruptive innovation in health care

Pharmacy Benefit agreements expand portfolio coverage to simplify access for eligible customers and providers

Results from Australia, Japan and Hong Kong highlight the potential impact across healthcare systems in the Asia-Pacific region

First patient successfully treated by Ajit Rao, MD, at The Mount Sinai Hospital, NY

Onyx™ 18, 34 Liquid Embolic System offers step forward in treatment options for cSDH

Now supported with effectiveness evidence, Medtronic DBS is the first and only U.S. FDA approved system to treat Dystonia symptoms

APHRS.25: Medtronic showcases breadth of defibrillation portfolio with outcomes from extravascular and transvenous defibrillation studies for the treatment of dangerous heart rhythm episodes

Confirmation comes from the position paper published by the Italian Society of Nephrology (SIN), expanding the indication of RDN to a complex and high-risk patient population

Recognition highlights Medtronic design excellence and commitment to improving patient lives

Medtronic also announced completion of enrollment in SPYRAL AFFIRM, which aims to build robust real-world evidence across traditionally underserved patient populations

Stedi Extra Support Guidewire Delivers Enhanced Support for Stability, Safety, and Predictability During Valve Deployment for Aortic Stenosis

Partnership launches AI solution to enhance predictive heart valve visualization and personalize valve treatment planning decisions enabling the future of TAVR for structural heart patients

Avalus Ultra valve expands Medtronic Cardiac Surgery’s portfolio of
cardiac surgical innovations

With this labeling approval, Medtronic continues to lead the way in advancing aortic care with clinical evidence for the treatment of ruptured abdominal aortic aneurysms (rAAA). Medtronic plc, a...

Findings highlight the potential of new investigational waveforms for the all-in-one mapping and dual-energy ablation system in advancing treatment for ventricular arrhythmia patients

Backed by exceptional clinical outcomes, the Neuroguard IEP™ System’s unique 3-in-1 design provides enhanced embolic protection when it matters most.1-5, † Medtronic, a global leader in...